Dapansutrile - CISMeF

Preferred Label : Dapansutrile;

NCIt definition : An orally bioavailable inhibitor of the innate immune signaling sensor nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD containing protein 3; NALP3), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, dapansutrile specifically binds to and inhibits NLRP3, the sensor component of the NLRP3 inflammasome, and prevents the formation of the NLRP3 inflammasome. This inhibits the production of the pro-inflammatory cytokines interleukin-1-beta (IL-1beta) and interleukin-18 (IL-18), which may prevent or reduce inflammation. NLRP3 plays an important role in immunity and inflammation.;

UNII : 2Z03364G96;

InChIKey : LQFRYKBDZNPJSW-UHFFFAOYSA-N;

CAS number : 54863-37-5;

Molecule name : OLT-1177; OLT 1177;

NCI Metathesaurus CUI : CL971857;

Details

Origin ID

C166608;

UMLS CUI

C4743069;

Automatic exact mappings (from CISMeF team)
- dapansutrile [MeSH concept]
- dapansutrile [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- dapansutrile [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
has_target
- NACHT, LRR and PYD Domains-Containing Protein 3 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients